Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics plc (NASDAQ: BCYC) has announced the granting of inducement awards to seven new employees on August 1, 2024. These awards consist of non-qualified share options to purchase a total of 71,200 ordinary shares. The options were granted under the company's 2024 Inducement Plan and approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $24.31 per share, which was Bicycle Therapeutics' closing trading price on July 31, 2024. The vesting schedule spans four years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remaining 75% vesting monthly over the subsequent 36 months. The vesting is subject to the employees' continued service with the company.
Bicycle Therapeutics plc (NASDAQ: BCYC) ha annunciato l'assegnazione di premi di incentivazione a sette nuovi dipendenti il 1° agosto 2024. Questi premi consistono in opzioni su azioni non qualificate per acquistare un totale di 71.200 azioni ordinarie. Le opzioni sono state assegnate nell'ambito del piano di incentivazione 2024 dell’azienda e approvate dal Comitato Risarcimenti in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Le opzioni hanno un prezzo di esercizio di $24,31 per azione, che corrisponde al prezzo di chiusura di Bicycle Therapeutics del 31 luglio 2024. Il calendario di maturazione si estende su quattro anni, con il 25% della maturazione che avviene al primo anniversario della data di inizio della maturazione e il restante 75% che matura mensilmente nei successivi 36 mesi. La maturazione è soggetta al continuo servizio dei dipendenti presso l’azienda.
Bicycle Therapeutics plc (NASDAQ: BCYC) ha anunciado la concesión de premios de incentivo a siete nuevos empleados el 1 de agosto de 2024. Estos premios consisten en opciones de acciones no calificadas para comprar un total de 71.200 acciones ordinarias. Las opciones se otorgaron bajo el Plan de Incentivo 2024 de la empresa y fueron aprobadas por el Comité de Compensación de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Las opciones tienen un precio de ejercicio de $24.31 por acción, que fue el precio de cierre de las acciones de Bicycle Therapeutics el 31 de julio de 2024. El calendario de adquisición se extiende a lo largo de cuatro años, con el 25% de la adquisición ocurriendo en el primer aniversario de la fecha de inicio del período de adquisición y el 75% restante adquiriéndose mensualmente durante los siguientes 36 meses. La adquisición está sujeta a la continuidad del servicio de los empleados con la empresa.
Bicycle Therapeutics plc (NASDAQ: BCYC)는 2024년 8월 1일에 7명의 새로운 직원에게 유인 상여를 수여했다고 발표했습니다. 이 상여는 총 71,200주 일반 주식을 구매할 수 있는 비자격 주식옵션으로 구성됩니다. 이 옵션은 회사의 2024년 유인 계획 하에 수여되었으며, 나스닥 상장 규칙 5635(c)(4)에 따라 보상 위원회에서 승인되었습니다.
옵션의 행사가격은 $24.31 per 주로, 이는 2024년 7월 31일 Bicycle Therapeutics의 종가입니다. 권리행사 일정은 4년으로 설정되어 있으며, 최초 1년 기념일에 25%가 발생하고 나머지 75%는 이후 36개월 동안 매월 발생합니다. 권리행사는 직원이 회사에 계속 근무하는 조건에 따라 이루어집니다.
Bicycle Therapeutics plc (NASDAQ: BCYC) a annoncé la remise de récompenses incitatives à sept nouveaux employés le 1er août 2024. Ces récompenses consistent en des options d'achat d'actions non qualifiées pour un total de 71 200 actions ordinaires. Les options ont été attribuées dans le cadre du Plan d'Incentive 2024 de l'entreprise et approuvées par le Comité des Rémunérations conformément à la règle de cotation Nasdaq 5635(c)(4).
Les options ont un prix d'exercice de 24,31 $ par action, correspondant au prix de clôture de Bicycle Therapeutics le 31 juillet 2024. Le calendrier de vesting s'étend sur quatre ans, avec 25 % de vesting à l'anniversaire d'un an de la date de début de vesting et les 75 % restants vesting mensuellement au cours des 36 mois suivants. Le vesting est soumis à la continuité du service des employés au sein de l'entreprise.
Bicycle Therapeutics plc (NASDAQ: BCYC) hat am 1. August 2024 die Gewährung von Anreizvergütungen an sieben neue Mitarbeiter bekannt gegeben. Diese Vergütungen bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von insgesamt 71.200 Stammaktien. Die Optionen wurden im Rahmen des Anreizplans 2024 des Unternehmens gewährt und vom Vergütungsausschuss gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
Die Optionen haben einen Ausübungspreis von $24,31 pro Aktie, was dem Schlusskurs von Bicycle Therapeutics am 31. Juli 2024 entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25% am einjährigen Jubiläum des Vesting-Beginns und die verbleibenden 75% monatlich über die folgenden 36 Monate fällig werden. Die Vesting-Bedingungen hängen von der Fortsetzung der Dienstverhältnisse der Mitarbeiter mit dem Unternehmen ab.
- Bicycle Therapeutics is attracting new talent with stock options as incentives
- The company has a structured vesting schedule to encourage employee retention
- Potential dilution of existing shareholders' equity due to new share options
Each option has an exercise price per share equal to
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801983908/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544
Media:
Deborah Elson
Argot Partners
media@bicycletx.com
212-600-1902
Source: Bicycle Therapeutics plc
FAQ
How many new employees received inducement awards from Bicycle Therapeutics on August 1, 2024?
What is the exercise price of the share options granted by Bicycle Therapeutics (BCYC)?
How many ordinary shares can be purchased with the non-qualified share options granted by Bicycle Therapeutics?
What is the vesting schedule for the share options granted by Bicycle Therapeutics (BCYC)?
